Navigation Links
DrugRisks Update: Use of NuvaRing Drops Amid Injury Allegations
Date:5/4/2013

New York, NY (PRWEB) May 04, 2013

The IUD safety advocates at DrugRisks.com are announcing new updates to the site for women who have used the vaginal ring contraceptive NuvaRing. This week, device maker Merck released records indicating use of the device have slowed since the end of last year*.

DrugRisks was designed to give patients using popular prescription drugs and devices the latest drug news, warnings, research and legal news. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice.

Health experts have linked contraceptives like NuvaRing to higher risks of blood clots than traditional birth control pills. Last year, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots**.

Almost 1,100 patients have already filed a NuvaRing lawsuit alleging blood clots in a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.

Now, DrugRisks has learned that the latest financial records from NuvaRing maker Merck show sales of the device dropped from $164 million at the end of 2012 to $151 million in the first quarter of 2013, a decline of 8%*.

Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact DrugRisks.com or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of federal MDL drug injury cases, DrugRisks only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

For more information on the research, NuvaRing side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisks.com.

*Merck, 5/1/13; merck.com/investors/financials/Merck_financial_disclosures_1Q13.pdf
**New England Journal of Medicine, 6/14/12; nejm.org/doi/full/10.1056/NEJMoa1111840

Read the full story at http://www.prweb.com/releases/nuvaring-side-effects/lawsuits-news/prweb10699808.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
2. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
5. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
6. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
7. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
8. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
9. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
10. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
11. HRT Update: Therapy May Reduce Fractures, Boost Some Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: